These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27327137)

  • 1. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
    Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
    Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS.
    Franzoni S; Vezzelli A; Turtoro A; Solazzo L; Greco A; Tassone P; Di Martino MT; Breda M
    J Pharm Biomed Anal; 2018 Feb; 150():300-307. PubMed ID: 29268195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
    Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
    Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.
    Di Martino MT; Arbitrio M; Fonsi M; Erratico CA; Scionti F; Caracciolo D; Tagliaferri P; Tassone P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861748
    [No Abstract]   [Full Text] [Related]  

  • 8. LNA-mediated microRNA silencing in non-human primates.
    Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
    Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.
    Straarup EM; Fisker N; Hedtjärn M; Lindholm MW; Rosenbohm C; Aarup V; Hansen HF; Ørum H; Hansen JB; Koch T
    Nucleic Acids Res; 2010 Nov; 38(20):7100-11. PubMed ID: 20615897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEI-complexed LNA antiseeds as miRNA inhibitors.
    Thomas M; Lange-Grünweller K; Dayyoub E; Bakowsky U; Weirauch U; Aigner A; Hartmann RK; Grünweller A
    RNA Biol; 2012 Aug; 9(8):1088-98. PubMed ID: 22894918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.
    Elmén J; Lindow M; Silahtaroglu A; Bak M; Christensen M; Lind-Thomsen A; Hedtjärn M; Hansen JB; Hansen HF; Straarup EM; McCullagh K; Kearney P; Kauppinen S
    Nucleic Acids Res; 2008 Mar; 36(4):1153-62. PubMed ID: 18158304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS.
    Franzoni S; Morbioli L; Turtoro A; Solazzo L; Greco A; Arbitrio M; Tagliaferri P; Tassone P; Di Martino MT; Breda M
    J Pharm Biomed Anal; 2020 Sep; 188():113451. PubMed ID: 32659676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration.
    Luan J; Fu J; Chen C; Jiao C; Kong W; Zhang Y; Chang Q; Wang Y; Li D; Illei GG; Kopp JB; Pi J; Zhou H
    Arthritis Res Ther; 2019 Dec; 21(1):276. PubMed ID: 31829247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical Synthesis of LNA-mCTP and its application for MicroRNA detection.
    Kore AR; Hodeib M; Hu Z
    Nucleosides Nucleotides Nucleic Acids; 2008 Jan; 27(1):1-17. PubMed ID: 18188765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-20a inhibition using locked nucleic acid (LNA) technology and its effects on apoptosis of human macrophages infected by Toxoplasma gondii RH strain.
    Rezaei F; Daryani A; Sharifi M; Sarvi S; Jafari N; Pagheh AS; Hashemi N; Hejazi SH
    Microb Pathog; 2018 Aug; 121():269-276. PubMed ID: 29800695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.